



65 West Watkins Mill Road
Gaithersburg, MD 20878
tel: 240-632-0740
fax: 240-632-0735
www.genvec.com

FOR IMMEDIATE RELEASE:

CONTACT:
Douglas J. Swirsky
Chief Financial Officer
(240) 632-5510
dswirsky@genvec.com

**GENVEC TO PRESENT AT THE 10TH ANNUAL
BIO CEO & INVESTOR CONFERENCE**

GAITHERSBURG, MD – February 5, 2008 – GenVec, Inc. (Nasdaq: GNVC) today announced that Paul H. Fischer, Ph.D., President and CEO, will present a company overview highlighting recent developments at the 10th Annual BIO CEO & Investor Conference on Monday, February 11, 2008 at 2:00 p.m. EST at the Waldorf Astoria Hotel in New York City.

A webcast of Dr. Fischer's presentation will be available both live and on replay. To access either the live or archived webcast, log on to GenVec's website at www.genvec.com, click on "Investor Relations," and proceed to "Webcasts & Data." The replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

###